Thyrocare Technologies Ltd · NSE:THYROCARE
Thyrocare Technologies — Q3 FY2020 Earnings Presentation
9 slides from Thyrocare Technologies's earnings presentation, Feb 3, 2020
Slide 1: Thyrocare - Think Thyroid. Think Thyrocare.
Thyrocare Think Thyroid. Think Thyrocare. February 03, 2020 The National Stock Exchange oflndia Limited The Bombay Stock Exchange Ltd Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Sandra (E), Mumbai - 400 051 Mumbai- 400 00 I Dear Sirs, Sub: Presentation on Quarterly Re
Slide 2: Disclaimer
Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, informatio
Slide 3: Highlights - Financial Performance - Thyrocare
Highlights - Financial Performance - Thyrocare Revenue from operations (in crore) Revenue from operations Q3-20 - Rs. 97.99 crore (+11.2%) [Q3-19 - Rs. 88.12 crore] 306.4 273.0 Samples processed Q3-20 – 0.45 crore (+4%) [Q3-19 – 0.44 crore] Patients served Q3-20 – 0.31 crore (+8%) [Q3-19 – 0.29 cror
Slide 4: Highlights - Financial Performance - Thyrocare (Continued..)
Highlights - Financial Performance – Thyrocare (Continued..) EBITDA Q3-20- Rs. 42.4 crore (+25%) (EBITDA margin 43.2%) [Q3-19 - Rs. 33.9 crore ] Normalized EBITDA margin Q3-20 – 42.5% [Q3-19 – 39% ] PAT Q3-20 - Rs. 29.9 crore (+33%) (PAT margin 30%) [Q3-19- Rs. 22.4 crore] Q3FY20 27.4% 11.9% 18.2% 4
Slide 5: Highlights - Financial Performance - Nueclear
Highlights - Financial Performance - Nueclear Revenue from operations (in crore) 26.0 Revenue from operations Q3-20 - Rs. 7.91 crore (-3%) 24.3 [Q3-19 - Rs. 8.16 crore] - Revenue from imaging services Q3-20 - Rs. 7.32 crore (-4%) [Q3-19 - Rs. 7.59 crore] - Two centres in Gujarat were non functional
Slide 6: Highlights - Financial Performance - Nueclear (Continued..)
Highlights - Financial Performance – Nueclear (Continued..) Employee benefits expense Employee/ consultant costs increased mainly on account of the centres newly started. Normalized EBITDA Q3-20 - Rs. 0.87 crore (EBITDA margin Other expenses 11%) [Q3-19 - Rs. 1.19 crore (15%)] More machines covered
Slide 7: Highlights - Financial Performance - Consolidated
Revenue from operations (in crore) Highlights - Financial Performance - Consolidated 331.8 Revenue from operations Q3-20 - Rs. 105.8 crore (+10%) [Q3-19 - 297.3 Rs. 96.3 crore] Normalized EBITDA Q3-20 - Rs. 42.5 crore (EBITDA margin 40%) [Q3-19 - Rs. 35.6 crore (37%)] 105.8 PAT Q3-20 - Rs. 27.5 cror
Slide 8: Adoption of Ind AS 116 "Leases"
Adoption of Ind AS- 116 “Leases” The Company has adopted Indian Accounting Standard 116 - Leases ("Standard"), with effect from 1 April 2019 using the modified retrospective method under the transitional provisions of the Standard and has taken the cumulative adjustment to retained earnings as on 1
Slide 9: Thank You
Then You
Thyrocare Technologies — Q3 FY2020 Earnings Presentation on 6ix